Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases

Antonio Cortese; Ramona Lucchetti; Alessio Altobelli; Antonella Conte; Marco Primavera; Guido Valesini; Enrico Millefiorini; Rossana Scrivo

doi:10.1016/j.msard.2019.08.006

Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases

Mult Scler Relat Disord. 2019 Oct:35:193-195. doi: 10.1016/j.msard.2019.08.006. Epub 2019 Aug 5.

Authors

Antonio Cortese¹, Ramona Lucchetti², Alessio Altobelli², Antonella Conte³, Marco Primavera⁴, Guido Valesini², Enrico Millefiorini⁴, Rossana Scrivo²

Affiliations

¹ Department of Human Neurosciences, Sapienza University of Rome, v.le dell'Università 30, 00185 Rome, Italy. Electronic address: antonio.cortese@uniroma1.it.
² Department of Internal Medicine and Medical Specialties, Rheumatology, Sapienza University of Rome, p.le Aldo Moro 5, 00185 Rome, Italy.
³ Department of Human Neurosciences, Sapienza University of Rome, v.le dell'Università 30, 00185 Rome, Italy; IRCCS Neuromed, via Atinense 18, 86077 Pozzilli, IS, Italy.
⁴ Department of Human Neurosciences, Sapienza University of Rome, v.le dell'Università 30, 00185 Rome, Italy.

PMID: 31398658
DOI: 10.1016/j.msard.2019.08.006

Abstract

The therapeutic approach to CNS demyelination associated to ankylosing spondylitis is a complex issue due to the contraindication of TNF inhibitors in demyelinating diseases. Secukinumab, a human IgG1κ monoclonal antibody that binds and inhibits IL-17A, was recently approved for the treatment of ankylosing spondylitis. We report the clinical cases of two patients affected by a CNS demyelinating disease and ankylosing spondylitis who were successfully treated with secukinumab, providing additional evidence of the feasibility of this therapeutic option when the use of TNF inhibitors is discouraged by challenging comorbidities.

Keywords: Ankylosing spondylitis; Clinical report; Multiple sclerosis; Secukinumab; TNF inhibitors.

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Demyelinating Diseases / complications
Demyelinating Diseases / drug therapy*
Female
Humans
Spondylitis, Ankylosing / complications
Spondylitis, Ankylosing / drug therapy*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
secukinumab